Literature DB >> 17249727

Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete.

Marc Stadler1, Jens Bitzer, Anke Mayer-Bartschmid, Hartwig Müller, Jordi Benet-Buchholz, Florian Gantner, Hans-Volker Tichy, Peter Reinemer, Kevin B Bacon.   

Abstract

The cinnabaramides A-G (1-7) were isolated from a terrestrial strain of Streptomyces as potent and selective inhibitors of the human 20S proteasome. Their chemical and biological properties resemble those of salinosporamide A, a recently identified lead compound from an obligate marine actinomycete, which is currently under development as an anticancer agent. Cinnabaramides F and G (6, 7) combine essential structural features of salinosporamide A and lactacystin and show about equal potency in vitro, with IC50 values in the 1 nM range. The properties and phylogenetic position of the producer organism, the production and isolation of compounds 1-7, their structure elucidation by MS and NMR, and their biological activities are reported. Additionally, an X-ray crystal structure was obtained from cinnabaramide A (1).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17249727     DOI: 10.1021/np060162u

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  17 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

2.  The discovery of salinosporamide K from the marine bacterium "Salinispora pacifica" by genome mining gives insight into pathway evolution.

Authors:  Alessandra S Eustáquio; Sang-Jip Nam; Kevin Penn; Anna Lechner; Micheal C Wilson; William Fenical; Paul R Jensen; Bradley S Moore
Journal:  Chembiochem       Date:  2011-01-03       Impact factor: 3.164

Review 3.  Carboxylases in natural and synthetic microbial pathways.

Authors:  Tobias J Erb
Journal:  Appl Environ Microbiol       Date:  2011-10-14       Impact factor: 4.792

4.  Bioinspired total synthesis and human proteasome inhibitory activity of (-)-salinosporamide A, (-)-homosalinosporamide A, and derivatives obtained via organonucleophile promoted bis-cyclizations.

Authors:  Henry Nguyen; Gil Ma; Tatiana Gladysheva; Trisha Fremgen; Daniel Romo
Journal:  J Org Chem       Date:  2010-11-03       Impact factor: 4.354

5.  Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.

Authors:  Andrew J Kale; Ryan P McGlinchey; Anna Lechner; Bradley S Moore
Journal:  ACS Chem Biol       Date:  2011-09-26       Impact factor: 5.100

Review 6.  The marine actinomycete genus Salinispora: a model organism for secondary metabolite discovery.

Authors:  Paul R Jensen; Bradley S Moore; William Fenical
Journal:  Nat Prod Rep       Date:  2015-05       Impact factor: 13.423

7.  Evolution of secondary metabolite genes in three closely related marine actinomycete species.

Authors:  Kelle C Freel; Sang-Jip Nam; William Fenical; Paul R Jensen
Journal:  Appl Environ Microbiol       Date:  2011-08-26       Impact factor: 4.792

8.  Concise total synthesis of (+/-)-salinosporamide A, (+/-)-cinnabaramide A, and derivatives via a bis-cyclization process: implications for a biosynthetic pathway?

Authors:  Gil Ma; Henry Nguyen; Daniel Romo
Journal:  Org Lett       Date:  2007-05-04       Impact factor: 6.005

9.  Biosynthesis of salinosporamides from alpha,beta-unsaturated fatty acids: implications for extending polyketide synthase diversity.

Authors:  Yuan Liu; Christopher Hazzard; Alessandra S Eustáquio; Kevin A Reynolds; Bradley S Moore
Journal:  J Am Chem Soc       Date:  2009-08-05       Impact factor: 15.419

Review 10.  Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.

Authors:  Barbara C Potts; Kin S Lam
Journal:  Mar Drugs       Date:  2010-03-25       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.